OBJECTIVES: Outpatient treatment of @entity1211 ( @entity1211 ) requires the selection of @entity1 with a low risk of @entity548 during the first few weeks of anticoagulation. The accuracy of four systems, originally derived for predicting @entity548 in @entity1211 treated with @entity2067 antagonists (VKAs), was assessed in @entity1211 @entity1 treated with @entity3925 . METHODS: All @entity1 treated with @entity3925 in the multinational EINSTEIN @entity1150 ( @entity1150 ) and @entity1151 ( @entity1151 ) trials were included. @entity548 was defined as >= 2  g/dL drop in hemoglobin or >= 2-unit blood transfusion, @entity548 in critical area, or @entity548 contributing to @entity204 . The authors examined the incidence of @entity548 in @entity1 with low-risk assignment by the systems of Ruiz-Gimenez et  al. (score  = 0 to 1), Beyth et  al. (score  =  0), Kuijer et  al. (score  =  0), and Landefeld and Goldman. (score  =  0). For clinical relevance, the definition of low risk for all scores except Kuijer includes all @entity1  <  65  years with no prior @entity548 history and no comorbid conditions (current @entity5 , @entity177 , @entity6 , @entity417 , prior @entity64 , or @entity583 ). RESULTS: A total of 4,130 @entity1 (1,731 with @entity1150 only, 2,399 with @entity1151 with or without @entity1150 ) were treated with @entity3925 for a mean (  SD) duration of 207.6 (  95.9) days. @entity548 occurred in 1.0% (40 of 4,130; 95% confidence interval [CI]  =  0.7% to 1.3%) overall. Rates of @entity548 for low-risk @entity1 during the entire treatment period were similar: Ruiz-Gimenez et  al., 12 of 2,622 (0.5%; 95% CI  =  0.2% to 0.8%); Beyth et  al., nine of 2,249 (0.4%; 95% CI  =  0.2% to 0.8%); Kuijer et  al., four of 1,186 (0.3%; 95% CI  =  0.1% to 0.9%); and Landefeld and Goldman, 11 of 2,407 (0.5%; 95% CI  =  0.2% to 0.8%). At 30  days, major bleed rates for low-risk @entity1 were as follows: Ruiz-Gimenez et  al., five of 2,622 (0.2%; 95% CI  =  0.1% to 0.4%); Beyth et  al., five of 2,249 (0.2%; 95% CI  =  0.1% to 0.5%); Kuijer et  al., three of 1,186 (0.3%; 95% CI  =  0.1% to 0.7%); and Landefeld and Goldman, seven of 2,407 (0.3%; 95% CI  =  0.1% to 0.6%). No low-risk @entity1 had a fatal bleed. CONCLUSIONS: Four scoring systems that use criteria obtained in routine clinical practice, derived to predict @entity548 risk with VKA treatment for @entity1211 , identified @entity1 with less than a 1% risk of @entity548 during full-course treatment with @entity3925 .

Comparison of Four Bleeding Risk Scores to Identify XXXX -treated @entity1 With @entity1211 at Low Risk for Major Bleeding.

@entity1 :: ('9606', 'Species') :: ['patient', 'patients'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity548 :: ('MESH:D006470', 'Disease') :: ['Major bleeding', 'low bleeding', 'bleeding', 'major bleeding'] @entity2067 :: ('MESH:D014812', 'Chemical') :: ['vitamin K'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus'] @entity1151 :: ('MESH:D011655', 'Disease') :: ['PE', 'pulmonary embolism'] @entity1150 :: ('MESH:D020246', 'Disease') :: ['deep vein thrombosis', 'DVT'] @entity177 :: ('MESH:D051437', 'Disease') :: ['renal insufficiency'] @entity3925 :: ('MESH:C503223', 'Chemical') :: ['rivaroxaban'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['VTE', 'acute venous thromboembolism'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity3925 :: (MESH:C503223,Chemical) :: ['Rivaroxaban']
